Luye Investment is dedicated in research, incubation and industrialization of life science technologies as well as products, with its focus on molecular diagnostics, regenerative medicine and cellular immunotherapy, making efforts to achieve precise medicine and cure serious diseases 

Molecular Diagnostics

Luye entered the molecular diagnosis area in 2015 and acquired Vela Diagnostics, a world leading provider of integrated molecular diagnostics. Established in 2011 and headquartered in Singapore, VelaDx comprises sales, service and distribution in key markets worldwide, offering a broad range of tests for infectious disease, immunosuppression, leukemia, oncology, etc. Pioneer in offering both qPCR and Next-Generation Sequencing (NGS) on one integrated workflow,providing innovative test and automatic data reporting solutions for the clinic.
VelaDx will synergize with Luye Group’s current business areas to establish an entire precision medical service chain from diagnostics to treatment.
Learn more:


Leading technologies

Launched the first NGS test for HIV drug resistance worldwide

Launched the first CE marked NGS assay for hepatitis C virus

HBV Quantitative assay receives CE-IVD approval

Zika virus molecular assay got the US FDA emergency use authorization

Launches early access program for liquid biopsy in oncology

Regenerative Medicine and Cell Technology

Main research fields involve preparation and preservation of immune cells and stem cells, new technology research and development of CAR-T and TCR-T, building of cell therapy technology platform, establishment, technology consulting and scientific research projects application of cell therapy lab  。

In Sep. 2017, Luye Life Sciences and Shin Nippon Biomedical sign a strategic cooperation agreement in Guangzhou. Luye will introduce regenerative medicine technologies from Shin Nippon Biomedical and jointly building Luye South China Regenerative Medicine Center.


Preparation & preservation of Immune cells

Preparation and preservation of stem cells

CAT-T, TCT-T and other new technologies development

鲁ICP备05023892号-5    LUYE All Rights Reserved Site map Privacy policy Terms of use